Exhibit 99.1
Contacts: | ||
Stereotaxis, Inc. | Euro RSCG Life NRP | |
314-615-6957 | 212-845-4253 | |
Jim Stolze, Chief Financial Officer | Ernie Knewitz (media) | |
jstolze@stereotaxis.com | ernie.knewitz@eurorscg.com | |
212-845-4269 | ||
Brian Ritchie (investors) | ||
brian.ritchie@eurorscg.com | ||
STEREOTAXIS ANNOUNCES THIRD QUARTER RESULTS
Management to Host a Conference Call Today At 5:00 PM Eastern Standard Time
St. Louis, MO, November 11, 2004 – Stereotaxis, Inc. (NASDAQ: STXS) today reported third quarter 2004 revenue of $5.7 million, a significant increase from the $1.0 million generated in the third quarter of 2003. Stereotaxis recognized revenue from the sale of six of its Niobe® advanced cardiology magnetic instrument control systems in the third quarter of 2004 compared to one system in the same quarter in 2003.
System revenues increased to $5.4 million in the current quarter from $0.9 million in the prior year quarter as a result of the increased number of units sold. Disposables, service and accessories revenue increased to $342,000, as compared to the $152,000 reported in the 2003 third quarter. The increase is attributable to the increased base of installed systems. Gross profit increased to $2.9 million, representing a 52% gross margin for the 2004 quarter, compared to $439,000, or 42% for the 2003 quarter. The improvement in gross margin is primarily attributable to engineered cost reductions on the systems delivered as well as the impact of the higher volume of systems recognized. As of September 30, 2004 there were 24 Niobe® systems sold and delivered worldwide.
Third quarter operating expenses were $8.4 million, which was $1.8 million higher than the third quarter 2003 operating expenses of $6.6 million. The increases in all categories of operating expenses were primarily attributable to increased headcount and costs related to expanded sales and marketing activities, as well as research and development programs. These additions are consistent with the significant increase in systems delivered in the current period and with the investment necessary to support the future growth of the Company.
The Company reported total revenue of $12.7 million for the nine months ended September 30, 2004, a significant increase over the $3.2 million in revenue reported for the nine months ended September 30, 2003. The increase was attributable to the 16 Niobe® systems sold and delivered through the 2004 period compared to five systems
sold and delivered in the corresponding prior year period, to an increase in average system selling price, as well as to the increased disposables, service and accessories revenues, which were $1.2 million for the 2004 period compared to the $293,000 recognized for the 2003 period. The increase in disposables, service and accessories revenue is attributable to the increased base of installed systems.
Net loss for the three months ended September 30, 2004 was $5.3 million or $0.34 per share on 15.6 million weighted average shares outstanding, versus a net loss of $6.2 million, or $4.68 per share on 1.3 million weighted average shares outstanding in the prior year quarter. Net loss for the nine months ended September 30, 2004 was $21.5 million, or $3.46 per share based on 6.2 million weighted average shares outstanding, versus $15.9 million, or $12.52 per share based on 1.3 million weighted average shares outstanding in the prior year period.
At September 30, 2004, Stereotaxis had purchase orders and other commitments for its Niobe® systems of approximately $20 million. The Company does not include orders for disposables, service or accessories in its backlog data.
Commenting on the results for the quarter, Bevil Hogg, President and CEO stated, “We are very pleased to have successfully completed our initial public offering in August, and with the revenue growth and overall operating results we achieved in the quarter. We are committed to further developing the value proposition of the Stereotaxis system and demonstrating its potential to revolutionize the practice of interventional medicine. Stereotaxis needs to continue to move toward profitability, while making the appropriate investments in the future of our products, and we are very focused on achieving both of these goals.”
Stereotaxis ended the September 2004 quarter with cash, cash equivalents and investments of approximately $60 million, as compared to approximately $26 million at December 31, 2003. The Company completed its initial public offering in August 2004. Total proceeds from the initial public offering, as well as the exercise of the underwriters’ over-allotment option, net of offering fees and underwriters’ discounts, were approximately $41.4 million. In addition, the Company received approximately $15.7 million in the first quarter of 2004 from the issuance of its Series E-2 convertible preferred stock. As a result of the initial public offering, the previously outstanding convertible preferred shares were converted to common shares. At September 30, 2004, the Company had 27,111,742 common shares outstanding.
The Company expects that system revenue for the fourth quarter of 2004 will approximate that of the third quarter. Operating expenses are expected to increase somewhat from third quarter amounts, reflecting the timing of expenditures related to certain research and development projects and to the inception of a remote ablation clinical trial in the United States. Going forward, Stereotaxis will provide full-year guidance for system revenue and operating expenses. The Company anticipates providing this guidance for 2005 when we issue our fourth quarter 2004 financial results.
The Company will host a conference call today at 5:00 p.m. Eastern Standard Time to discuss the results for the quarter. To participate in the conference call, please dial 800.231.5571 (Domestic) or 973.582.2703 (International) a few minutes before 5:00 p.m. ET. A replay of the conference call will be available from 7:00 p.m. ET on November 11, 2004 until 7:00 p.m. ET on November 18, 2004. The replay dial in number is 877.519.4471 (Domestic) or 973.341.3080 (International). The replay pin number is 5294249.
The call will also be available on the Internet live and for seven days thereafter at the following URL:
http://phx.corporate-ir.net/playerlink.zhtml?c=179896&s=wm&e=959153
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S. and Europe.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
STEREOTAXIS, INC.
BALANCE SHEETS
| September 30, 2004 | December 31, 2003 | |||||||
| (Unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 47,776,711 | $ | 21,356,247 | ||||
Short-term investments | 10,074,302 | 5,124,365 | ||||||
Accounts receivable, net allowance of $140,918 and $116,725 in 2004 and 2003 | 7,456,885 | 559,721 | ||||||
Current portion of long-term receivables | 153,896 | 155,331 | ||||||
Inventories | 4,120,622 | 4,430,228 | ||||||
Prepaid expenses and other current assets | 2,348,305 | 876,264 | ||||||
Total current assets | 71,930,721 | 32,502,156 | ||||||
Property and equipment, net | 1,587,057 | 2,309,467 | ||||||
Intangible assets | 1,844,444 | 1,944,444 | ||||||
Long-term receivables | 307,791 | 465,993 | ||||||
Other assets | 124,804 | 101,359 | ||||||
Long-term investments | 1,872,708 | — | ||||||
Total assets | $ | 77,667,525 | $ | 37,323,419 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Current maturities of long-term debt | $ | 1,183,975 | $ | 2,289,314 | ||||
Accounts payable | 2,585,977 | 1,697,497 | ||||||
Accrued liabilities | 6,069,617 | 4,936,233 | ||||||
Deferred revenue | 2,746,098 | 814,393 | ||||||
Total current liabilities | $ | 12,585,667 | $ | 9,737,437 | ||||
Long-term debt, less current maturities | 1,166,667 | 2,243,768 | ||||||
Other liabilities | 25,481 | 75,786 | ||||||
Stockholders’ equity: | ||||||||
Convertible preferred stock, issued in series, par value $0.001; 10,000,000 and 65,000,000 shares authorized at 2004 and 2003, respectively, 0 and 61,055,286 issued and outstanding at 2004 and 2003, respectively; liquidation preference of $146,819,436 at December 31, 2003. | — | 61,055 | ||||||
Common stock, par value of $0.001; 100,000,000 and 80,000,000 shares authorized at 2004 and 2003, respectively; 27,148,261 and 1,515,150 issued at 2004 and 2003, respectively | 27,148 | 1,515 | ||||||
Additional paid-in capital | 173,851,049 | 113,921,587 | ||||||
Deferred compensation | (573,064 | ) | (835,801 | ) | ||||
Treasury stock, 36,519 and 18,316 shares at 2004 and 2003, respectively | (162,546 | ) | (17,750 | ) | ||||
Notes receivable from sales of stock | (171,032 | ) | (448,413 | ) | ||||
Accumulated deficit | (108,949,343 | ) | (87,415,765 | ) | ||||
Accumulated other comprehensive loss | (132,502 | ) | — | |||||
Total stockholders’ equity | 63,889,710 | 25,266,428 | ||||||
Total liabilities and stockholder’s equity | $ | 77,667,525 | $ | 37,323,419 | ||||
STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
Three months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2004 | 2003 | 2004 | 2003 | |||||||||||||
Systems revenue | $ | 5,371,216 | $ | 888,588 | $ | 11,518,568 | $ | 2,150,619 | ||||||||
Disposables, service and accessories revenue | 342,395 | 152,344 | 1,177,867 | 293,453 | ||||||||||||
Other revenue | — | — | — | 725,900 | ||||||||||||
Total revenue | 5,713,611 | 1,040,932 | 12,696,435 | 3,169,972 | ||||||||||||
Cost of revenue | 2,729,518 | 601,622 | 7,706,949 | 2,185,126 | ||||||||||||
Gross margin | 2,984,093 | 439,310 | 4,989,486 | 984,846 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 4,189,578 | 3,574,679 | 14,019,807 | 9,171,117 | ||||||||||||
General and administration | 1,667,119 | 1,289,896 | 4,676,451 | 3,570,231 | ||||||||||||
Sales and marketing | 2,518,445 | 1,718,203 | 7,949,104 | 4,105,610 | ||||||||||||
Total operating expenses | 8,375,142 | 6,582,778 | 26,645,362 | 16,846,958 | ||||||||||||
Operating loss | (5,391,049 | ) | (6,143,468 | ) | (21,655,876 | ) | (15,862,112 | ) | ||||||||
Interest income | 186,095 | 64,117 | 457,300 | 241,957 | ||||||||||||
Interest expense | (112,535 | ) | (114,761 | ) | (335,002 | ) | (325,919 | ) | ||||||||
Net loss | $ | (5,317,489 | ) | $ | (6,194,112 | ) | $ | (21,533,578 | ) | $ | (15,946,074 | ) | ||||
Net loss per common share: | ||||||||||||||||
Basic and diluted | $ | (0.34 | ) | $ | (4.68 | ) | $ | (3.46 | ) | $ | (12.52 | ) | ||||
Weighted average shares used in computing net loss per common share: | ||||||||||||||||
Basic and diluted | 15,567,170 | 1,323,817 | 6,219,334 | 1,273,666 | ||||||||||||